Àλ縻 |
|
|
|
|
Á¦1ºÎ - ±âÃÊ°úÇÐÀÚ¸¦ À§ÇÑ ÀÓ»óÁ¾¾çÇÐ
|
|
Session 1 |
09:00-10:15 |
1) ¾ÏÀÇ Áø´Ü, º´±â¼³Á¤, Ä¡·áÀÇ ¿øÄ¢ |
¼Û±³¿µ (°¡Å縯ÀÇ´ë) |
2) ¹æ»ç¼±Ä¡·áÀÇ ¿øÄ¢ |
°Çöö (¼¿ïÀÇ´ë) |
3) º´¸® ¹ÙÀÌ¿À¸¶Ä¿ °Ë»çÀÇ ÀÌÇØ |
¾È¼ö¹Î (¼º±Õ°üÀÇ´ë) |
|
|
|
Break
|
10:15-10:35 |
|
|
|
Session 2 |
10:35-11:50 |
1) Ç×¾ÏÄ¡·áÀÇ ¿øÄ¢ |
±èâ°ï (¿¬¼¼ÀÇ´ë) |
2) ¾Ï ÀÓ»ó½ÃÇèÀÇ ÀÌÇØ I (Phase, design, endpoint) |
±èÇüµ· (¿ï»êÀÇ´ë) |
3) ¾Ï ÀÓ»ó½ÃÇèÀÇ ÀÌÇØ II (RECIST, CTCAE) |
À°Á¤È¯ (¼¿ïÀÇ´ë) |
|
|
|
Lunch Break
|
11:50-13:00 |
|
|
|
Á¦2ºÎ - ¾Ï ¿¬±¸¸¦ À§ÇÑ ¸é¿ªÇÐ/À¯ÀüüÇÐÀÇ ±âÃÊ
|
|
¾Ï ¿¬±¸¸¦ À§ÇÑ ¸é¿ªÇÐÀÇ ±âÃÊ |
13:00-14:40 |
1) Understanding anti-tumor immune responses |
½ÅÀÇö (KAIST) |
2) PD-1, T cell exhaustion, and immune checkpoint inhibitors
|
ÀÓ¼¼Áø (¼º±Õ°üÀÇ´ë) |
3) TIGIT and LAG3, targets of novel immune checkpoint inhibitors |
¹ÚÀ± (KIST) |
4) Current trends in personalized cancer vaccines |
ÀÓ¿ÁÀç (Ƽ½ì·ÎÁö) |
|
|
|
Break
|
14:40-15:00 |
|
|
|
¾Ï ¿¬±¸¸¦ À§ÇÑ À¯ÀüüÇÐÀÇ ±âÃÊ |
15:00-16:40 |
1) Epigenomic and epitranscriptomic alterations in cancer |
Á¶¼º¿± (¼¿ïÀÇ´ë) |
2) Real world applications of whole-genome sequencing |
ÀÌÁ¤¼® (KAIST) |
3) Current and future applications of circulating tumor DNA assays |
±è¿µ°ï (¼º±Õ°üÀÇ´ë) |
4) Navigating the cancer evolution using single-cell genomics |
±è±ÔÅ (¾ÆÁÖÀÇ´ë) |